Volume : 11, Issue : 12, December – 2024
Title:
FORMULATION AND CHARACTERIZATION OF RIVASTIGMINE NANOPARTICLES
Authors :
S.Divya, T.Ram Chander
Abstract :
Nanoformulations have the potential to greatly improve our understanding of the causes and treatments for neurodegenerative and other disorders. Many factors were effectively tuned in developing novel nanoformulations for treating Alzheimer’s disease using this approach. The coated nanoparticles were created using a set core-to-polymer ratio of 1:1, which controls the release pattern of the drug contained for an extended length of time. The coated nanoparticles that were produced had a size of less than 200 nm and slowly released the drug from the 66.83% drug-entrapped nanoparticles over 24 hours (98.46%). The best formula was selected because it was physically and chemically stable throughout three months at various temperatures. Thus, to get around the drug’s low bioavailability problems, produced rivastigmine nanoparticles could be employed as an alternative delivery mechanism.
Keywords: Nanoformulations, Alzheimer’s disease, Rivastigmine, core-to-polymer ratio, drug release.
Cite This Article:
Please cite this article in press T.Ram Chander et al., Formulation And Characterization Of Rivastigmine Nanoparticles .,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Qiao R, Jia Q, Huwel S, Xia R, Liu T, Gao F, Galla HJ, Gao M. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS nano. 2012Apr24;6(4):3304-10
2. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids and Barriers of the CNS. 2014Dec;11:1-32
3. Pinheiro RG, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for targeted brain drug delivery: what do we know?. International Journal of Molecular Sciences. 2021Oct28;22(21):11654
4. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European journal of pharmaceutics and biopharmaceutics. 2020Apr1;149:192-217
5. Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge University Press. 2001 May 31
6. Li X, Tsibouklis J, Weng T, Zhang B, Yin G, Feng G, Cui Y, Savina IN, Mikhalovska LI, Sandeman SR, Howel CA. Nano carriers for drug transport across the blood-brain barrier. Journal of drug targeting. 2017Jan2;25(1):17-28
7. Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert opinion on drug delivery. 2013Jul1;10(7):889-905
8. Bicker J, Alves G, Fortuna A, Falcão A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. European Journal of Pharmaceutics and Biopharmaceutics. 2014Aug1;87(3):409-32
9. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. Journal of inherited metabolic disease. 2013May;36:437-49
10. Naqvi S, Panghal A, Flora SJ. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Frontiers in Neuroscience. 2020Jun9;14:494
11. Feng L, Wang H, Xue X. Recent progress of nanomedicine in the treatment of central nervous system diseases. Advanced Therapeutics. 2020May;3(5):1900159
12. Nguyen TT, Nguyen TT, Vo TK, Nguyen MK, Van Vo T, Van Vo G. Nanotechnology-based drug delivery for central nervous system disorders. Biomedicine & Pharmacotherapy. 2021Nov1;143:112117
13. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Frontiers in chemistry. 2021Apr23;9:580118
14. Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics. 2020Mar;12(3):288
15. Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Kumar NS, Vekariya RL. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC advances. 2020;10(45):26777-91
16. Salunkhe SS, Bhatia NM, Bhatia MS. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain. Drug Delivery. 2016May3;23(4):1306-16
17. Costa CP, Moreira JN, Lobo JM, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharmaceutica Sinica B. 2021Apr1;11(4):925-40
18. Costa CP, Barreiro S, Moreira JN, Silva R, Almeida H, Sousa Lobo JM, Silva AC. In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals. 2021Jul23;14(8):711
19. Costa C, Moreira JN, Amaral MH, Lobo JS, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. Journal of Controlled Release. 2019Feb10;295:187-200
20. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics. 2021Jul31;13(8):1183.